Inverted covariate effects for mutated 2nd vs 1st wave Covid-19: high temperature spread biased for young - Seligmann, Hervé; Iggui, Siham; Rachdi, Mustapha; Vuillerme, Nicolas; Demongeot, Jacques (medRxiv, 2020)
Background Here, we characterize COVID-19 2nd waves, following a study presenting negative associations between 1st wave COVID-19 spread parameters and temperature;Methods Visual examinations of daily increase in confirmed COVID-19 cases in 124 countries, determined 1st and 2ndwaves in 28 countries;Results 1st wave spread rate increases with country mean elevation, temperature, time since wave onset, and median age. Spread rates decrease above 1000m, indicating high UV decrease spread rate. For 2nd waves, associations are opposite: viruses adapted to high temperature and to infect young populations. Earliest 2nd waves started April 5-7 at mutagenic high elevations (Armenia, Algeria). 2nd waves occurred also at warm-to-cold season transition (Argentina, Chile). Spread decreases in most (77%) countries. Death-to-total case ratios decrease during the 2ndwave, also when comparing with the same period for countries where the 1st wave is ongoing. In countries with late 1st wave onset, spread rates fit better 2nd than 1st wave-temperature patterns; In countries with ageing populations (examples: Japan, Sweden, Ukraine), 2nd waves only adapted to spread at higher temperatures, not to infect children.Conclusions 1st wave viruses evolved towards lower spread and mortality. 2nd wave mutant COVID-19 strain(s) adapted to higher temperature, infecting children and replace (also in cold conditions) 1st wave COVID-19 strains. Counterintuitively, low spread strains replace high spread strains, rendering prognostics and extrapolations uncertain.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research has been exempted of IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript